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Abstract: The presence of small amounts of circulating nucleic acids in plasma and serum 
(CNAPS) is not a new finding. The verification that such amounts are significantly increased 
in cancer patients, and that CNAPS might carry a variety of genetic and epigenetic alterations 
related to cancer development and progression, has aroused great interest in the scientific 
community in the last decades. Such alterations potentially reflect changes that occur during 
carcinogenesis, and include DNA mutations, loss of heterozygosity, viral genomic integration, 
disruption of microRNA, hypermethylation of tumor suppressor genes, and changes in the 
mitochondrial DNA. These findings have led to many efforts toward the implementation of 
new clinical biomarkers based on CNAPS analysis. In the present article, we review the main 
findings related to the utility of CNAPS analysis for early diagnosis, prognosis, and monitoring 
of cancer, most of which appear promising. However, due to the lack of harmonization of 
laboratory techniques, the heterogeneity of disease progression, and the small number of 
recruited patients in most of those studies, there has been a poor translation of basic research 
into clinical practice. In addition, many aspects remain unknown, such as the release mechanisms 
of cell-free nucleic acids, their biological function, and the way by which they circulate in the 
bloodstream. It is therefore expected that in the coming years, an improved understanding of the 
relationship between CNAPS and the molecular biology of cancer will lead to better diagnosis, 
management, and treatment.
Keywords: plasma, cancer, clinical tool, microRNA, heterozygosity, tumor suppressor genes, 
viral genomic integration, biomarkers
Introduction
According to the World Health Organization, cancer mortality will increase by 45% 
from 2007 to 2030 due to the demographic increase and population aging.1 For that 
reason, many efforts have been made to find sensitive and specific biomarkers for early 
diagnosis, prognosis, and management of patients during treatment and follow-up.
A variety of tumors secrete proteins into the bloodstream that are routinely 
used as tumor markers in clinical practice, such as the prostate-specific antigen in 
prostate cancer, the alpha-fetoprotein in hepatocarcinoma, the carcinoembryonic 
antigen (CEA) in colon cancer, the cancer antigen (CA) 15.3 in breast cancer, and the 
CA19.9 in pancreatobiliary tumors.2 However, those techniques might lack sensitivity 
in nonsecretory tumors, and might give positive results due to inflammatory processes 
or benign illnesses, limiting their specificity. In addition, there are no known serum 
markers for most tumors, which highlights the need for extensive study of the biology 
of tumors to propose new clinical tools. Indeed, it is expected that an improvement in 
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the knowledge of the molecular biology of cancer will lead 
to earlier diagnosis and more effective treatments.
Cancer is produced and progresses as a consequence 
of complex and gradual processes, in which a variety of 
genetic and epigenetic alterations are involved (eg, muta-
tions, hypermethylations), and which mainly result in 
uncontrolled cell growth. Those molecular alterations can be 
found in the bloodstream,3 which suggests that we could find 
understanding of the molecular biology of a specific cancer 
in plasma (Figure 1). This was the start point for the study 
of the so-called cell-free nucleic acids in plasma and serum 
(CNAPS) as cancer biomarkers.
Although in the last decades the CNAPS concept has gen-
erated a considerable interest in the research community, the 
concept was first suggested many years before this. Specifi-
cally, Mandel and Métais4 first reported the existence of cell-
free DNA (cfDNA) in plasma in the mid-twentieth century. 
However, their study had scarce impact until 30 years later, 
when Leon et al5 demonstrated that cancer patients had higher 
cfDNA levels than normal people and that patients with per-
sistently high levels of cfDNA after treatment had a worse 
prognosis than those in whom cfDNA levels decreased.
Some years later, Stroun et al6 suggested that at least 
some of the cfDNA in serum or plasma was derived from the 
primary tumor, but this hypothesis was only confirmed later 
by two nearly parallel studies that described the presence of 
KRAS mutations in plasma from patients with pancreas neo-
plasm7 and acute myelogenous leukemia.8 Those discoveries 
were the milestones that opened new pathways for cancer 
biology research and the search for new clinical tools.
The term “CNAPS” refers to different types of cell-free 
nucleic acids (cfNAs), such as genomic DNA (gDNA), mito-
chondrial DNA (mitDNA), viral DNA and RNA, messenger 
(m)RNA, and microRNA (miRNA), which have recently been 
reported to be present in plasma.3,9–13
In spite of the increasing number of studies focused on 
CNAPS, and of the technological improvements, nowadays, 
some important aspects of CNAPS biology remain unknown, 
such as their release mechanisms,14 method of circulation,15–18 
and biological role in cancer progression.19 Limiting factors in 
the study of CNAPS have mainly been the lack of harmoniza-
tion of laboratory techniques, the heterogeneity of the disease 
progression, and the small number of recruited patients in 
most of studies, which is for some authors9 an example of 
poor translation of basic research into clinical practice.
Circulating cfDNA
Biology of cfDNA
It has been reported that cfDNA is a double-stranded mol-
ecule of low-molecular weight that is fragmented into short 
(70–200 base pairs) and long sections (up to 21 kilobases).20 
The analysis of those fragments has deepened understanding 
Analyses of plasma cfDNA:
• Quantitation of total cfDNA
• Quantitation of tumor cfDNA
• DNA integrity index
• Detection of molecular alterations harbored
in primary tumors:
    Mutations in oncogenes and/or tumor suppressor genes
    (eg, KRAS, APC, p53, PIK3CA, BRAF, EGFR, HER2)
    Methylation of genes
    (eg, p16, APC, SEPT9, RASSF1A, GSTP1, DAPK)
    Loss of heterozygosity
• Detection of viral DNA
   (eg, Epstein-Barr virus, human papillomavirus)
• Quantitation of mitochondrial cfDNA
• Mitochondrial DNA integrity
Analyses of plasma cfRNA:
• Quantitation of specific mRNA sequences
(eg, metastasin, cytokeratin 19, mammaglobin, squamous 
   cell carcinoma-antigen, human telomerase reverse transcriptase) 
• Quantitation of specific miRNA sequences 
(eg, miR-1, miR-15, miR-17-3p, miR-21, miR-25, miR-29a, 
   miR-30d, miR-44, miR-92, miR-92a, miR-106a, miR-128b, 
   miR-141, miR-221m, miR-223, miR-361-3p, miR-486, miR-625) 
Figure 1 Graphic representation of the analyses of cell-free nucleic acid (cfNA) circulating in plasma that have been tested in cancer patients and that might serve as clinical 
markers.
Abbreviations: mRNA, messenger RNA; cfDNA, cell-free DNA; cfRNA, cell-free RNA; miRNA, micro RNA.
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of their origin.21 For some researchers, the main source of 
cfDNA has been necrosis,22,23 while others have proposed 
apoptosis in view of the size of the DNA fragments detected 
in plasma.20 In addition, several studies have suggested the 
active release of cfDNA by cells,14,24 and specifically by 
lymphocytes.25 Therefore, two possible sources of cfDNA, 
non-mutually exclusive, have been considered: passive 
release through cell death and active release by cell secretion. 
Nonetheless, recent studies using genome-wide sequencing 
of plasma DNA have demonstrated that such DNA contains 
representation of the entire tumor genome and reflects the 
clonal genomic evolution of tumors.26
Theoretically, CNAPS would be rapidly degraded in 
the bloodstream by nucleases; it has even been proven that 
mutated cfDNA degrades faster than non-mutated cfDNA.27,28 
However, the enzymatic action might be limited because at 
least part of cfDNA appears to be protected by being com-
plexed or particulate with special protective characteristics 
against enzymatic degradation.29–31 A decreased activity of 
DNase has also been observed in plasma from cancer patients, 
which might be another reason for the high levels of cfDNA 
found in plasma.31
Quantitation of cfDNA in plasma  
and serum
Many studies have confirmed the early findings of Leon et al.3,9 
In fact, high concentrations of cfDNA have been reported in 
plasma and serum from patients with various cancers, such 
as cancer of the colon,33 lung,34–36 breast,37,38 stomach,39 and 
esophagus.40 The clinical value of such quantitation for dif-
ferential diagnosis was suggested in a large study by Shapiro 
et al,41 who showed that patients with benign gastrointestinal 
diseases had a lower mean concentration of plasma cfDNA 
(118 ng/mL) than cancer patients (412 ng/mL).
Several studies have proposed the use of the quantita-
tion of cfDNA in plasma as a method for screening colon,33 
breast,38 and lung cancers36,42 among others. In colon cancer 
patients, such a method has showed an even better sensitivity 
than CEA quantitation.33 In breast cancer patients, plasma 
levels of cfDNA have also been related to clinicopathologi-
cal variables such as size, tumor stage, lymphadenopathies, 
human epidermal growth factor receptor 2 (HER2)/neu level 
and state.38 In lung cancer, it has even been suggested that 
the concentration of circulating DNA might be a risk factor 
for the presence of the illness and a prognostic index during 
follow-up.36
However, in extensive revisions, the use of quantitation of 
cfDNA in plasma as a unique marker has been questioned9 
and has even been proposed as inadvisable in lung cancer43 
and associated with CA125 in ovarian cancer.44 In addition, 
it is remarkable that overlapping concentrations of cfDNA 
are found in healthy individuals under physiological stress 
(eg, physical exercise) or in patients affected by other pathologi-
cal processes, such as, inflammation, trauma, or sepsis.3,45–47
The validation of the clinical utility of methods for 
detection and quantitation of plasma cfDNA has probably 
failed because of technical limitations, particularly those 
related to sensitivity and specificity. There have been some 
attempts to establish reference values for different types of 
cancer;48 however, the lack of harmonization in the laboratory 
techniques (quantitative polymerase chain reaction [PCR], 
spectrophotometry, fluorimetry, etc) and the low number 
and heterogeneity of patients enrolled in each study, have 
prevented the achievement of suitable statistical power and 
the establishment of reference patterns.3,9,10
Although, theoretically, the levels of cfDNA in plasma 
might be affected by several clinicopathological features 
such as tumor size, tumor stage, or metastasis,9,38 no direct 
relationship between these features has been proven, as 
Lecomte et al discussed in their review focused on colorec-
tal cancer.49 García-Olmo et al have conducted studies in 
animal models to deepen understanding of cfDNA kinetics 
and have repeatedly shown that non-mutated DNA levels 
are not significantly related to tumor size or metastasis.50,51 
In fact, they found that large amounts of non-tumor DNA 
are released during tumor progression and, in particular, at 
the early stages, suggesting that there is active interaction 
between tumor and non-tumor cells.50
It is probable that the quantitation of cfDNA in plasma 
will be of most clinical value during disease monitoring.42 
It has been reported that plasma levels decreased in cancer 
patients after surgical treatments33,35,37,39,40 and/or chemoradio-
therapy,52 sometimes reaching levels similar to those measured 
before treatment.35,39,40 In addition, patients who maintained 
high levels of cfDNA in plasma either did not respond to the 
treatment or had a high risk of relapse.5,33–37,53
Circulating nucleosomes, as degradation products of 
necrotic tumor cells in the bloodstream, have also been 
examined and quantified by enzyme-linked immunosorbent 
assay techniques.16 The DNA of necrotic cells, after being 
phagocytosed by macrophages,23 might be released to the 
bloodstream inside those structures, which protect it from 
enzymatic degradation. Nucleosomes have been found in 
healthy subjects and in patients with benign diseases,15 thus, 
their value as a screening method appears to be limited; 
however, there is some evidence to support their utility 
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for cancer monitoring. Specifically, during chemotherapy 
treatments, an initial increase of the levels of nucleosomes has 
been observed in plasma, which might be related to apoptosis 
provoked by treatment, and a later decrease in patients who 
had a good response to the treatment.15,54,55
Molecular alterations of cfDNA
Most of the molecular alterations found in cfDNA circulating 
in plasma reflect the genetic and epigenetic changes found in 
primary tumors and, thus, the analysis of such tumor cfDNA 
might be valuable for tumor diagnosis and monitoring. Highly 
sensitive methods are required to detect those alterations 
among larger quantities of non-altered cfDNA molecules and, 
for this reason among others, extremely varied results have 
been reported.3,20,56
Following, we review the alterations in cfDNA most 
frequently found in plasma from cancer patients and tumor-
bearing animals.
Integrity of the DNA strand
Using PCR, Wang et al57 found that long DNA fragments, 
related to necrosis phenomena, could be distinguished from 
shorter fragments, produced by physiological apoptosis 
phenomena. These findings gave rise to the so-called integrity 
index, based on the ratio between long and short cfDNA 
fragments. The integrity index was established based on 
gynecologic and breast cancers,57 with the results obtained 
from 61 patients compared with those from 65 patients 
without neoplastic disease. It was found that the area under 
the curve for the DNA integrity index was 0.911 in cancer 
patients in relation to patients without cancer, with 100% 
sensitivity and 62% specificity. The authors suggested that 
the integrity index provides a simple and inexpensive way 
to detect cancer.57
A number of transposable elements of the genome, such 
as ALU and LINE1 sequences, can be easily detected and 
have been associated with tumor necrosis. Specifically, ALU 
sequences are short elements (typically 300 nucleotides in 
length) that account for more than 10% of the human genome. 
Umetani et al developed a method to measure the integrity 
of cfDNA in serum using quantitative PCR for ALU repeats, 
and suggested that the integrity index is increased at the early 
stages of the disease and a promising molecular biomarker 
for detecting colorectal and breast cancer.58,59 Moreover, it 
might serve as a sensitive method to detect nodal metastases 
in the early stages, having an even higher predictive value 
than the clinicopathological variables commonly used, such 
as tumor size and stage.59
In a recent study in patients with hepatitis B virus-related 
hepatocellular carcinoma, the integrity index was associated 
with tumor size, TNM Classification of Malignant Tumors 
(TMN) stage, and nodal metastasis, and showed a more 
discriminatory power than total cfDNA concentration.60
Further, in other recent studies, the clinical value of the 
integrity index has been demonstrated, not only for the diag-
nosis but also the monitoring of the disease. For example, it 
has been found that the integrity index decreases in parallel 
to the response to surgical treatments for head and neck 
tumors61 and melanoma,62 to chemotherapy in leukemia,63 
to radiotherapy in nasopharyngeal tumors,64 and to chemo-
radiotherapy in colorectal cancer.52 Moreover, it has been 
reported that patients with high concentrations of integrity 
DNA had shorter disease-free intervals.64
Alterations in the integrity of DNA have also been 
detected in other organic liquids, such as urine, and can be 
used in the early diagnosis of bladder cancer without cytol-
ogy.65 Some authors have emphasized that the integrity index 
meets many of the requirements of a universal biomarker;10 
however, other studies have not supported this idea.66
Gene mutations
As previously mentioned, many studies have shown that gene 
mutations found in primary tumors can be also detected in 
cfDNA circulating in plasma. The literature reports a wide 
percentage range of patients in whose plasma such mutations 
have been detected. The differences between studies might be 
due to technical reasons, since sensitive techniques are needed 
to detect very small amounts of mutated DNA among larger 
quantities of un-mutated DNA, which has a dilution effect.
The gene that has most frequently been examined is 
the KRAS oncogene, which is mutated in variable rates in 
high-incidence tumors, such as colon, pancreas, lung and 
thyroid tumors,9 and has intrinsic characteristics that make 
it useful as a marker.49 In fact, the prevalence of KRAS muta-
tions is near 50%. Such mutations occur in the early stages 
of carcinogenesis and are mostly produced at specific sites 
(particularly in codon 12), which facilitate its detection using 
PCR-based techniques.
With respect to colorectal cancer, KRAS mutations have 
been found in 40%–50% of patients, and have also been 
detected in the plasma or serum of 25%–30% of patients.49 
Kopreski et al67 tried to correlate the detection of KRAS muta-
tions in plasma with clinicopathological findings detected by 
colonoscopy. They enrolled into their study one of the largest 
series of colorectal cancer patients that has ever been enrolled 
into similar studies, and detected KRAS mutations in plasma 
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from 83% of patients whose tumors had such mutations.67 
Moreover, they also found that some patients with apparently 
normal colonoscopy had KRAS mutations in plasma, which 
might be related to the presence of precancer lesions, thus 
suggesting the technique’s suitability for early diagnosis and 
screening.67
In a review by Sorenson,68 the author defended the detec-
tion of KRAS mutations in plasma as a specific marker for 
gastrointestinal tumors, with 2.5% false positives, although 
the review of studies showed that the concordance with 
KRAS plasmatic mutations with respect to primary tumor 
was only 50%. It has also been reported that other mutations, 
different from those in primary tumors, can be detected in 
plasma from cancer patients, which might be due to clone 
heterogeneity in tumors.69
In patients with pancreas cancer, it has been shown that 
detecting KRAS mutations in plasma is useful for early diag-
nosis as a complementary marker together with other serum 
markers (eg, CA19.9).70 Other researchers have also used it 
for disease monitoring.71
In a prospective study conducted by Gormally et al72 of a 
healthy population, KRAS mutations were detected in plasma 
from 1.2% subjects and p53 mutations in 3.6%. The authors 
suggested that KRAS mutations are detectable in plasma 
before the diagnosis of bladder cancer. In contrast, KRAS 
mutations have been detected by other researchers in up to 
30% of healthy individuals;9 this has been interpreted as a 
limitation of the diagnosis and screening value.
With respect to mutations in other genes, Chen et al73 used 
an ultrasensitive technique to detect p53 mutations in plasma 
from patients with Stage II and III breast cancer, and their 
results showed a correlation between such detection and the 
clinical course of the disease after therapy.
The value of detection of tumor mutations in plasma for 
monitoring the response to treatment has been analyzed in 
several studies. Diehl et al74 showed that the detection and 
quantification of mutated cfDNA in plasma from colon 
cancer patients undergoing surgery and chemotherapy were 
more useful for monitoring than the quantitation of CEA in 
serum. In addition, a recent study has shown that the use 
of panels with the most frequent mutations in colorectal 
cancer (APC, KRAS, TP53, PIK3CA, and BRAF) was more 
useful than using CEA and CA19.9 levels.75 Further, it has 
been suggested that, in the postoperative period, the levels 
of mutated KRAS in plasma are a more powerful predictor 
of recurrence than Dukes stage.76
In breast cancer patients, the presence of amplified 
HER2 has been demonstrated in circulating cfDNA during 
follow-up.77 This led the researchers to propose such ampli-
fication as a marker for prognosis and response to treatment 
with monoclonal antibodies, such as trastuzumab.77 A recent 
study has provided proof of the concept that tumor cfDNA 
circulating in plasma represents a highly sensitive biomarker 
of tumor burden in metastatic breast cancer.78 Specifically, 
the researchers developed new methods to identify somatic 
genomic alterations (point mutations, structural variants) 
and designed personalized assays to quantify tumor cfDNA 
circulating in plasma from 30 patients. They found that levels 
of tumor cfDNA showed a greater dynamic range and greater 
correlation with changes in tumor burden than did CA15-3 
or circulating tumor cells.78
Many chemotherapeutic agents act on pathways in which 
KRAS, BRAF, EGFR, or p53 are involved.79,80 For this reason, 
in many cases, it is important to know the mutation status 
for predicting the response to treatment and monitoring the 
disease. The analysis of plasma offers a noninvasive and 
quick way to find out this information and, in this sense, 
it has been reported that detection of EGFR mutations in 
plasma might be useful to predict disease progression, 
disease-free intervals, and drug resistances in patients with 
lung cancer.79–81 Moreover, it has recently been reported that 
sequencing of cancer exomes in serial plasma samples might 
be useful to track genomic evolution of metastatic cancers 
in response to therapy.26 The researchers described a nonin-
vasive approach for characterizing cancer exomes in plasma 
that might enable detailed and comprehensive evaluation of 
clonal genomic evolution associated with treatment response 
and resistance.26
Summarizing, patients whose tumors have specific muta-
tions might be monitored by analyzing the tumor cfDNA in 
their plasma samples.10,26,78
Gene hypermethylations
Some tumors are related to specific epigenetic alterations 
(eg, methylation), leading to changes in the expression 
of promoters of suppressor genes, which results in their 
silencing. Such alterations occur early in tumorigenesis 
and in DNA fragments that are rich in cytosine and guanine 
(CpG islands). The first observations were reported in 1999 
by Esteller et al82 in non-small cell lung carcinoma; now, 
the detection of these alterations represents one of the most 
promising advances in cancer diagnosis.
Epigenetic alterations are not tumor specific; moreover, 
there are some genes that are frequently hypermethylated and 
silenced in different types of tumors. In fact, many studies 
have analyzed panels of genes to increase sensitivity.83–85 
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Thus, it is essential to select accurately the genes to analyze 
for each type of cancer to improve the sensitivity of the 
analyses. Some of the most common aberrant methylations 
affect the p16 tumor suppressor gene and have been found 
in patients with liver, lung, and breast tumors.82,86,87 Other 
suppressor genes frequently hypermethylated are SEPT9, 
RASSF1A, GSTP1, and DAPK, among others.
The clinical value of the detection of hypermethylated 
genes in plasma has been shown in different types of cancer 
such as breast,84,85 colon,53 liver,88 esophagus,89 and urological 
tumors,90 as well as in hematologic diseases.91 It has been 
suggested that the methylated status of cfDNA circulating 
in plasma might be a tool for prognosis stratification and 
the prediction of the response to some chemotherapeutics 
agents,8,9,92 disease-free interval, and risk of relapse.53,88,89
Hypermethylations have also been detected in cfDNA 
from other body fluids such as urine.90 Specifically, the 
presence of tumor cfDNA has been reported in 70% of 
urine samples, suggesting its utility for the diagnosis and 
monitoring of patients with urologic tumors such as bladder, 
prostate and kidney cancers.90
Microsatellite alterations
“Microsatellites” are repeating sequences of one to six 
nucleotides that are scattered along the genome; their 
function is unknown. Such sequences serve to identify “loss 
of heterozygosity” (LOH), which is a frequent alteration 
of tumor DNA characterized by the loss of an allele when 
compared with matched normal DNA from the same 
individual. LOH indicates the absence of a functional tumor 
suppressor gene by deletion. In contrast, some tumors have 
abnormally long or short microsatellites as a result of a 
defective DNA repair process; this is termed “microsatellite 
instability” (MSI).
It has been reported that LOH and MSI can be detected 
in cfDNA circulating in plasma; however, discrepancies 
between tumor DNA and plasma cfDNA have been reported.2 
Although the detection of such alterations in plasma is more 
probable in advanced stages, some researchers have sug-
gested a potential value for such detection at the diagnosis 
stage of breast93 and ovarian cancers,44 which may have an 
even higher sensitivity than the quantitation of cfDNA.44
To increase the sensitivity of this kind of marker, they 
have been tested in combination with several other plasma 
markers, such as methylations and prostate-specific antigen 
in prostate cancer.94 In addition, panels of microsatellites 
are often used to improve sensitivity.95,96 For example, in a 
recent prospective study in breast cancer patients, LOH was 
determined by PCR-based microsatellite analysis using a 
panel of eight polymorphic markers.96 The researchers found 
that LOH at those markers was significantly correlated with 
tumor stage, tumor size, lymph node metastasis, positive 
progesterone, and HER2 status.96 Moreover, LOH at a marker 
mapping to cyclin D2 correlated with shorter overall survival. 
Thus, the researchers concluded that the improved detection 
of LOH on cfDNA provides important information on DNA 
losses of tumor suppressor genes (TIG1, PTEN, cyclin D2, 
RB1, and BRCA1) in breast cancer. In particular, loss of the 
cyclin D2 gene may become an important prognostic marker 
easily detectable in the peripheral blood.96
Prior to that interesting study, it was reported that the 
assessment of microsatellite status in plasma might be a 
useful predictive tool for prognosis in breast carcinoma,97 to 
monitor the response to surgical treatment; in oral squamous 
cell carcinoma;95 and to biochemotherapy in metastatic 
melanoma.98
viral DNA
Viruses are the main etiologic factors of a number of tumors 
and can be detected in plasma by PCR-based techniques. In 
fact, the presence of cfDNA of Epstein–Barr virus (EBV) 
has been demonstrated in nasopharyngeal cancers, Hodgkin’s 
disease, and Burkitt lymphoma; human papillomavirus in cer-
vical tumors; and hepatitis B virus in hepatocellular tumors, 
certain lymphomas, and gastric cancers.3,10,12,99–102
The presence of EBV sequences in plasma has been the 
focus of many studies, perhaps due to the high incidence of 
nasopharyngeal carcinoma in Asian countries. It has been 
shown that the detection of EBV in plasma is a powerful 
diagnostic tool and its quantitation might have prognostic 
value.103 In addition, detection of EBV in plasma has also 
been associated with response to radiotherapy, disease recur-
rence, and survival.12
mitDNA
Although the study of the genetic and epigenetic alterations 
of gDNA is the cornerstone of cancer research, the discov-
ery of specific alterations in mitDNA in cancer patients104 
has opened new routes in the search for clinical tools. The 
detection of aberrant changes in mitDNA is becoming an 
important tool for the early diagnosis of cancer, which is in 
part due to the fact that the analysis of mitDNA has some 
advantages over that of gDNA.11 These advantages can be 
summarized as follows.
•	 The mitochondrial genome is shorter and more simply 
organized than nuclear DNA. These unique properties 
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make the screening of a mitochondrial genome much 
easier and more cost-effective.
•	 mitDNA’s high number of copies, in comparison to 
nuclear DNA, make it a much more sensitive method.
•	 mitDNA fragments have been detected in different body 
fluids from cancer patients at early stages, such as in the 
blood,104,105 saliva,106 urine,107 and sputum.
The alteration of mitDNA as a response to adaptation 
changes was first described in the early twentieth century, when 
it was termed the “Warburg effect.”108 Alterations in mitDNA 
have been found in the plasma of healthy individuals109 and have 
also be related to tumor development and progression.110 The 
alterations, which are point mutations, deletions, insertions, and 
quantitative changes,11 have been detected in a wide range of 
tumors, such as breast, colon, liver, head, and neck and lung.111 
It is important to highlight that the identification of mutations 
in a concrete region typical to many tumors is referred to as the 
“D-loop,” which may have diagnostic value.104
The presence of mitDNA mutations has been reported in 
plasma and serum samples from patients with hepatocellular, 
pancreatic, prostatic, colorectal, and esophageal cancers, 
among others.112–116 Moreover, several studies have suggested 
that quantitation of mitochondrial cfDNA in plasma might 
serve as a clinical tool,117,118 and may even have a higher 
diagnostic value than gDNA in some cases.118 Specifically, 
Kohler et al117 compared the levels of gDNA and mitDNA 
in plasma from patients with benign and malignant breast 
tumors with those from healthy controls. They concluded that 
both nuclear and mitochondrial cfDNA have potential as bio-
markers in breast tumor management; however, the nuclear 
cfDNA showed greater sensitivity and specificity. Zachariah 
et al118 conducted a study in 104 women with ovarian cancer, 
benign tumors, and endometriosis, and compared the levels of 
gDNA and mitDNA in plasma in these patients. Patients with 
epithelial ovarian cancer had significantly higher amounts 
of nuclear and mitochondrial cfDNA than the other women, 
but the levels of cfDNA in plasma were related to neither 
pathological parameters nor CA125 levels. In addition, the 
researchers found that quantitation of mitDNA was a unique 
way to differentiate between patients with ovarian cancer 
and endometriosis.118
Other studies have used “mitochondrial DNA integrity,” 
which has been defined as the ratio between long and short 
fragments of mitDNA.119 It has been reported that such an 
index might differentiate between patients with urologic 
malignancies (renal, prostate, and bladder tumors) and 
healthy subjects, with a sensitivity of 84% and a specificity 
of 97%.119
Finally, it has been reported that some mitDNA poly-
morphisms are associated with cancer development, thus a 
genetic analysis of such polymorphisms could help to identify 
target populations to establish screening programs.11
Circulating cell-free RNA (cfRNA)
Biology of cfRNA
The origin of the cfRNA circulating in plasma, its role, and 
its release mechanisms are yet unknown. The existence of 
cfRNA in blood was reported many years ago when, in 1987, 
Wieczorek et al120 found RNA in proteolipid complexes in the 
serum of cancer patients.121 However, the potential clinical value 
of the detection of cfRNA in plasma did not attract the attention 
of researchers until 1999, when two parallel studies reported 
the detection of tyrosinase mRNA in patients with metastatic 
melanoma122 and mRNA associated with EBV in patients with 
nasopharyngeal carcinoma.123 Many studies have subsequently 
reported the presence of specific mRNA in plasma from patients 
with a variety of cancers including colon,124–126 breast,127,128 
prostate,129,130 melanoma,122 lung,131 and thyroid.132
It was theorized that the fragility of cfRNA in serum or 
plasma – due to the fast enzymatic degradation it undergoes, 
which is increased in cancer patients133 – might make its 
detection difficult. However, it was found that the molecules 
are more stable than it was presumed,134 possibly due to 
protection by vesicle-like structures.
The origin of cfRNA remains less clear than that of 
cfDNA.21,24 It has been proposed that apoptosis might be 
involved in the release of cfRNA, and that its association with 
apoptotic bodies might explain the resistance to nucleases 
in blood.31 However, other hypotheses for the circulation of 
cfRNA have also been put forward, such as it occurring within 
lipoprotein complexes24 or being in other actively-released 
particles, such as exosomes.121
Ng et al135 examined the particle-associated nature of 
circulating cfRNA by filtering plasma samples from healthy 
subjects and cancer patients through material with different 
pore sizes. They found greater amounts of particle-associated 
mRNA in cancer patients than in healthy subjects, suggesting 
that most of the cfRNA not associated with particles had 
degraded.135
Detection and quantitation of cfRNA  
in plasma and serum
The use of cfRNA as a biomarker has several advantages 
including the ease with which plasma or serum samples 
for testing can be obtained, which makes it feasible for 
the monitoring of metastatic disease and even for wide 
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screenings. However, RNA molecules are fragile, so high 
sensitivity techniques with simultaneous internal controls 
are necessary.136
One of the most analyzed mRNAs in plasma is that of 
the human transcriptase reverse telomerase (hTERT), which 
corresponds to a ribonucleoprotein involved in the repair and 
lengthening of telomeres in eukaryotic cells. This mRNA is 
overexpressed in a variety of tumors.124,126,128,129,137–140 However, 
cfRNA is not specific to cancer patients and can also be found 
in healthy volunteers or in those suffering trauma.46,141
In breast cancer patients, using PCR-based techniques, 
hTERT mRNA has been detected in serum, even in patients 
with localized disease.128 Silva et al127 observed that analysis 
of specific mRNA epithelium (cytokeratin 19) in plasma, in 
combination with mammaglobin, facilitates the detection 
of a greater number of positive cases than does analysis of 
tumor cfDNA (73% versus [vs] 29%). Moreover, detection 
of epithelial mRNA has been found to be related to tumor 
size and proliferation rate.127 In addition, El-Abd et al have 
suggested the utility of the detection of metastasin mRNA 
in serum as a survival marker, with high sensitivity (85%) 
and specificity (100%).142
In colon cancer patients, an adequate correlation between 
hTERT levels in plasma and tumor stage has been observed, 
which has led such a quantitation to be proposed as a tool for 
screening, monitoring,137 and response to treatment.140
With respect to lung cancer, Miura et al138 analyzed 
plasma samples from 112 patients and 80 healthy subjects 
to detect and quantify hTERT and epidermal growth factor 
receptor (EGFR) mRNAs. They found that the sensitivity 
and specificity in lung cancer diagnosis were, respectively, 
89% and 73% for hTERT mRNA, and 71% and 80% for 
EGFR mRNA. Moreover, they found that the number of 
copies of hTERT mRNA significantly decreased after 
surgical treatment.138 These data led the researchers to 
suggest that hTERT mRNA, especially when combined 
with EGFR mRNA, may be an excellent biomarker for 
pulmonary malignancies to diagnose and assess clinical 
stage.138 In addition, it has been suggested that the detection 
of heterogeneous nuclear ribonucleoprotein-B1 mRNA and 
HER2/neu-specific mRNA might have diagnostic value in 
lung cancer.143
In esophagus cancer patients, the detection of squamous 
cell carcinoma-antigen mRNA (SCC-Ag mRNA) by real-
time PCR was shown to be the best predictive factor for 
recurrence in patients.144
In hepatocellular cancer, the detection of hTERT mRNA 
in serum has been suggested to be of diagnostic value, with a 
sensitivity of 88% and a specificity of 70%.139 Moreover, the 
researchers reported a good correlation between the levels of 
hTERT mRNA in plasma and clinicopathological parameters, 
such as degree of differentiation.139 However, other studies 
have shown no correlation with clinicopathological variables 
such as tumor size.145
cfRNA can be detected in other body fluids such as saliva 
and urine, and satisfactory results have been reported for its 
detection in these as a marker for the diagnosis of mouth and 
urological cancers, respectively.136
miRNA
The discovery of miRNA in 1993 was a milestone in cell 
biology research. From that moment, the number of identi-
fied miRNAs steadily increased and, to date, more than 
900 human miRNAs have been discovered.
“miRNAs” are small noncoding molecules of 
18–22 nucleotides that regulate gene expression, acting at a 
post-transcriptional level. It is known that a unique miRNA 
is able to regulate multiple different mRNAs, so that it might 
potentially alter the function of multiple channels.13
miRNAs have been demonstrated to play important roles 
in control of cell proliferation, cell differentiation, and apop-
tosis, thus their dysregulation contributes to tumor develop-
ment. Moreover, it has been demonstrated that miRNAs can 
function as potential oncogenes or oncosuppressor genes, 
depending on the cellular context and on the target genes 
they regulate.146 Aberrant expression of miRNAs has been 
associated with multiple types of cancer including colon,147–150 
lung,151–154 breast,155 prostate,156 gastric,157 and esophagus,158 
as well as lymphoma.159
miRNAs have been detected in the plasma and serum of 
animals and humans, and in both healthy subjects and cancer 
patients. The first evidence that miRNAs might serve as sero-
logical biomarkers of solid tumors was provided by Mitchell 
et al156 and Chen et al.147 miRNAs circulating in plasma have 
some advantages as clinical markers compared with other 
forms of cfRNA, since they have a remarkable resistance to 
endogenous and exogenous ribonuclease activity, extreme 
pH conditions, and freeze–thaw cycles, whereas synthetic 
miRNAs are promptly degraded.160
Circulating miRNAs have been found packaged into 
various membrane-bound vesicles such as exosomes,18 
microvesicles and apoptotic bodies (reviewed by Zandberga 
et al),160 and also in lipoprotein complexes.141 This is probably 
the main reason for the high resistance of plasma miRNAs, 
which makes their detection by PCR-based techniques 
easy. In addition, miRNAs are tissue specific, which allows 
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the development of panels to help in the diagnosis of 
tumors of unknown origin.156,161,162 Moreover, they are not 
only detectable in the bloodstream but also in other body 
fluids.18,163 Thus, the use of miRNAs as serological biomarkers 
is a very attractive option and research in this field continues 
to increase.
miR-21, probably the most analyzed miRNA, is often 
overexpressed in many types of tumors.164 Nonetheless, a 
number of miRNAs have been demonstrated to have potential 
value as serological biomarkers in cancer, including miR-1, 
miR-10b, miR-17-92, miR-24, miR-92a, miR-122, miR-141, 
miR-155, miR-195, miR-221, and miR-375.165
The diagnostic value of miRNA panels appears to be 
superior to that of individual miRNAs.160 Specific expression 
patterns of serum miRNAs have been identified for lung 
cancer, colorectal cancer, and diabetes, providing evidence 
that serum miRNAs contain fingerprints for a variety of 
diseases.147
It has been demonstrated that colorectal cancer patients 
have an miRNA serum profile significantly different to that 
of healthy subjects. Specifically, 69 miRNAs have been 
detected in sera from colorectal cancer patients but not in 
those from healthy subjects.147 Moreover, colorectal cancer 
patients have been found to share a large number of serum 
miRNAs with lung cancer patients.147 In addition, Ng et al148 
analyzed plasma samples from 90 colorectal cancer patients 
and 50 healthy subjects and found that miR-17-3p and 
miR-92 were overexpressed in patients, which suggested 
the potential diagnostic value of such plasma levels, with a 
sensitivity of 89% and specificity of 70%. Subsequent studies 
have supported Ng et al’s findings, including that by Huang 
et al,149 who showed that levels of miR-29a and miR-92a in 
plasma discriminate colorectal cancer, with 83% sensitivity 
and 85% specificity. In a recent revision, the prediction value 
of three miRNAs (miR-221, miR-141, and miR-29a) has been 
highlighted as 3 independent factors of wrong predictions in 
different clinical stages.166
The increased expression of miR-21, miR-106, and miR-
15 has been observed in breast cancer patients compared with 
that observed in healthy subjects, in both tissues and serum, 
and those levels have been found associated with tumor stage 
and the presence of lymph node metastases.155 With respect to 
lung cancer, Wang et al152 and Liu et al153 observed high levels 
of miR-21 in the plasma of cancer patients compared with 
that in healthy individuals. These levels were also associated 
with TNM stage and the presence of lymph node metastasis. 
Further, Roth et al154 suggested that miR-361-3p and miR-
625 might have a protective effect on the development of 
non-small cell lung cancer, while its quantification in serum 
might have the diagnostic potential to detect that cancer, 
particularly in smokers.
The most comprehensive search to date for circulating 
miRNAs with prognostic significance was performed by Hu 
et al,151 who analyzed a large cohort of 303 patients and found 
that four plasma miRNAs (miR-486, miR-30d, miR-1, and 
miR-449) were independent predictors of average survival. 
In prostate cancer, Mitchell et al156 were able to distinguish 
patients with cancer from healthy individuals by serum levels 
of miR-141. Finally, Lawrie et al demonstrated that serum 
levels of miR-21 were associated with the disease-free inter-
val in patients with diffuse B-cell lymphoma.159
In future, the search for circulating miRNAs of clinical 
value is likely to be carried out at the same time as the study 
of many unknown aspects, such as the role of circulating 
miRNAs, the cell types that secrete them, and the regulation 
of this secretion.
Conclusion
The data reviewed in the present article suggest that the 
clinical value of cfNAs circulating in plasma is already 
more than a theoretical idea, since the characterization and 
the quantitation of such nucleic acids (NAs) have been shown 
to be complementary tools in the diagnosis, prognosis, and 
management of cancer patients (Figure 2). However, some 
important questions remain unanswered, largely because most 
studies have been underpowered as well as because there has 
been no adequate standardization of laboratory techniques, 
Trauma Sepsisinflammatory diseases
Necrosis/apoptosis
active release
Diagnosis Prognosis Treatment
Laboratorial detection
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PCR, sequencing, fluorimetry,
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Clinicopathological
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Figure 2 Schematic representation of the outline of the present review.
Abbreviations: CNAPS, cell-free nucleic acids in plasma and serum; PCR, 
polymerase chain reaction; TNM, TNM Classification of Malignant Tumors.
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which complicates the comparison of results from different 
groups.3,9,10 Thus, it appears necessary to drive initiatives 
directed toward validating and verifying laboratory methods 
and procedures for required molecular tests before their use 
in clinical testing. For this, it might be useful to network, as 
has been demonstrated by successful previous initiatives.167 
Methods based on sequencing (genome-wide sequencing, 
exome sequencing, etc) appear to be the definitive tool for 
making the analysis of cfDNA for cancer monitoring useful, 
since it allows for personalized assays.26,78
However, plasma cfNAs have yet many enigmatic 
aspects. Elucidation of these might lead us to a revision in the 
way the pathobiology of cancer is conceived. It is likely that 
many molecular pathways are involved in the origin of such 
NAs, since various results point in non-exclusive different 
directions. It has been postulated that the cfNAs circulating 
in plasma are not merely biological waste, but that they may 
be directly involved in the development of metastases, pos-
sibly through transfection-like uptake by susceptible cells.168 
This hypothesis, the “genometastasis theory,” is supported by 
strong evidence – namely, the observation that plasma from 
cancer patients can transfect and oncogenically transform 
cultured cells.169,170
Regardless, no conclusive explanation of the circulation 
mechanism of cfNAs yet exists. Several groups have 
suggested a relationship between the presence of cfNAs 
in plasma and the presence of exosomes.121,171 Thus, 
it appears feasible that at least part of plasma cfNAs 
circulates within exosomes. This finding correlates with 
the idea that plasma cfNAs might have a role in tumor 
progression, since it has been proven that exosomes are 
able to transfer their RNA content to cells, and that this 
RNA can be functional in its new location.18 It has even 
been demonstrated that miRNAs are transferred during 
immune synapsis and are able to modulate gene expression 
in recipient cells.172 Moreover, cross-talk between tumor-
derived exosomes and host cells, such as bone marrow 
progenitor cells, appears undeniable.173 Thus, transfer of 
genetic material from exosomes to cells might be involved 
in the recruitment and metastatic conversion of host cells. 
Conversely, it might be possible to exploit this phenomenon 
for therapeutic purposes and, perhaps, it will be proper to 
focus the development of clinical tools on the detection 
and analysis of NAs containing microparticles. Certainly, 
at this moment, a robust body of research on exosomes and 
microvesicles exists and increased understanding of such 
particles in future will shed light on cancer pathobiology 
and offer promising perspectives on clinical tools.
Thus, although the origin and the circulation mechanism 
of plasma cfNAs remain unclear, there is strong evidence to 
suggest that such NAs will become useful biomarkers for 
the diagnosis and monitoring of cancer disease and that they 
might be essential to tumor development and progression.
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